The instruction for medical use
of Tserakson® medicine
the Trade name
the International unlicensed
name Tsitikolin Lekarstvennaya
the Tablet form, film coated 500 mg
One tablet contains
active agent – tsitikolin sodium of 522.5 mg (500 mg
of a tsitikolin are equivalent)
excipients: talc, magnesium stearate, silicon dioxide colloidal anhydrous, sodium of a kroskarmeloz, the castor oil hydrogenated, cellulose microcrystalline
structure of a cover: talc, magnesium stearate, the titan E171 dioxide, polyethyleneglycol 6000, eudragit E
of the Tablet of oblong shape, film coated, white color, with marking of C500
of Psikhoanaleptiki. Psychostimulants and nootropa. Psychostimulants and nootropa others. Tsitikolin
ATH N06BX06 Code
Tsitikolin Pharmacokinetics Absorption properties is well absorbed at intake. Absorption after oral administration almost full, and bioavailability approximately same, as well as after intravenous administration.
Drug is metabolized in intestines and in a liver with formation of sincaline and cytidine. After administration of drug the concentration of sincaline in plasma significantly increases.
Tsitikolin is substantially distributed in structures of a brain, with rapid implementation of fractions of sincaline in structural phospholipids and fractions of cytidine – in cytidine nucleotides and nucleic acids. Tsitikolin gets into a brain and is actively built in cellular, cytoplasmic and mitochondrial membranes, forming a part of fraction of structural phospholipids.
Only of 15% of the entered dose of a tsitikolin is brought out of an organism: less than 3% – kidneys and through intestines and about 12% with the exhaled CO2 (carbon dioxide).
In excretion of a tsitikolin with urine it is possible to allocate 2 phases: the first phase lasting about 36 hours during which clearance rate decreases and the second phase during which the speed of excretion decreases much more slowly. The same is observed with the exhaled CO2 – clearance rate quickly decreases approximately in 15 hours, and then decreases much more slowly.
of Tserakson® – nootropic drug. Improves transfer of nervous impulses in cholinergic neurons – positively influences plasticity of neuronalny membranes and function of receptors. Improves a cerebral blood stream, strengthens metabolic processes in a brain, activates structures of a reticular formation of a brain and restores consciousness in a traumatic brain damage.
Цераксон® is a sincaline source, increasing synthesis of acetylcholine and stimulates biosynthesis of structural (basic) phospholipids in a membrane of neurons that promotes improvement of function of membrane mechanisms, including, to functioning of ion-exchange pumps and the receptors shipped in them which modulation is a necessary condition of neurotransfer.
Цераксон® softens the symptoms which are observed in a hypoxia and ischemia of a brain, including a memory impairment, emotional lability, lack of initiative, difficulties during the performing of daily actions and self-service.
Цераксон® it is effective in treatment of cognitive, sensitive and motive neurologic disorders of a degenerative and vascular etiology.
– a stroke and its consequences
– a craniocereberal injury and its consequences
– the cognitive, sensitive and motive neurologic
disorders caused by degenerative changes and vascular disorders
the Route of administration and doses
the Recommended dosage from 500 to 2000 mg a day (1 – 4 tablets) depending on disease severity.
The dose can be changed according to the recommendation of the doctor.
People of advanced age
correction of a dosage for this age group is not required.
Very seldom (& lt, 1/10.000) (including individual reactions).
– allergic reactions, a small tortoiseshell, a dieback, erubescence up to purple coloring, a skin itching, hypostases, development of an acute anaphylaxis
– a headache, dizziness, hallucinations, excitement, insomnia, temperature increase, feeling of heat, a tremor
– nausea, vomiting, diarrhea
– increase or short-term lowering of arterial pressure
of the Contraindication
– hypersensitivity to drug components
– a state with a high tone of parasympathetic nervous system is possible (vagotonia)
– children’s age up to 6 years (the tableted form)
Tsitikolin enhances effects of L-dihydroxyphenylalanin. It is not necessary to appoint along with the medicines containing meklofeksonat.
instructions Use in pediatrics
In children’s practice appoint medicine if the expected therapeutic advantage exceeds possible risk. The age and the mode of dosing is defined by the attending physician individually.
Pregnancy and the period of a lactation
Though proofs of risk at use of drug during pregnancy or in the period of a lactation were not received, drug is appointed if the expected advantage exceeds potential risk for a fruit and the child.
The feature of influence of medicine on ability to run the vehicle or potentially dangerous Tsitikolin mechanisms does not influence ability to control of vehicles and use of mechanisms.
Symptoms: strengthening of side effects of drug.
The form of release and packing
On 5 tablets place in blister strip packagings from a film of polyvinylchloride and aluminum foil.
On 4 planimetric packs together with the instruction for medical use in the state and Russian languages put in a pack cardboard.
To Store storage conditions at a temperature from 15ºC to 30ºC
to Store out of children’s reach!
not to apply a period of storage after the expiration date specified on packing.
According to the prescription
the Producer Ferrer Internasyonal, S.A., Barcelona, Spain
the Owner of the registration certificate
Ferrer Internasyonal, S.A., Spain.
The address of the organization accepting claims from consumers on quality of products (goods) in the territory of the Republic of Kazakhstan:
Representative office Takeda Osteuropa Holding GmbH (Austria) in
Kazakhstan Almaty, Shashkin St. 44 Phone number
(727) 2444004 Fax number (727) 2444005
E-mail address of DSO-KZ@takeda.com